Precise experiments have revealed for the first time how Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS), progresses on a genetic and cellular level. The work comprises tens of thousands of minuscule measurements of spinal tissue and opens new avenues for developing potential treatments for the disease, which affects around 450,000 people worldwide.